Literature DB >> 11075991

Multiple primary tumors as an indicator for p16INK4a germline mutations in pancreatic cancer patients?

B Gerdes1, D K Bartsch, A Ramaswamy, M Kersting, A Wild, M Schuermann, M Frey, M Rothmund.   

Abstract

Multiple primary tumors in pancreatic cancer patients might indicate a genetic predisposition to the development of malignancies. In this study we evaluated whether the mutation rate of the TP53 and p16INK4a genes of pancreatic cancers differs in pancreatic cancer patients with and without multiple primaries. Furthermore, we investigated whether pancreatic cancer patients with multiple primaries carry germline mutations in either p16INK4a, TP53, or BRCA2 tumor suppressor genes to detect a genetic alteration that predisposes to the development of different primaries. Fourteen (23%) of 60 pancreatic cancer patients developed histologically verified additional primaries during their lifetimes. Normal constitutional and tumor DNA of the 14 patients with a positive cancer history, but negative family history, were analyzed for p16INK4a, TP53, and BRCA2 mutations by single-strand conformational variant (SSCV) analysis and direct sequencing. Hypermethylation of the p16INK4a promoter region in pancreatic cancers was identified by methylation-specific polymerase chain reaction (PCR; MSP). Four of 14 pancreatic carcinomas carried somatic intragenic p16INK4a mutations, and another four tumors revealed hypermethylation of the p16INK4a promoter region. Somatic intragenic TP53 mutations were identified in six of 14 tumors. None of the pancreatic cancer patients carried TP53 or BRCA2 germline mutations. In contrast, one of 14 pancreatic cancer patients with multiple primaries carried the p16INK4a mutation A68V in his germline. This mutation was localized in the conserved second ankyrin repeat of p16INK4a and did not occur in 100 control patients. The frequency of somatic TP53 and p16INK4a mutations in pancreatic cancer is similar in patients with and without multiple primaries. TP53 and BRCA2 germline mutations seem not to be significantly associated with the occurrence of multiple primaries in pancreatic cancer patients. However, p16INK4a germline mutations might be causative for tumor development in some pancreatic cancer patients with multiple primaries. The genetic investigation of patients with accumulation of different cancers even without a positive family history may be a new approach for the understanding of the relation of different cancers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11075991     DOI: 10.1097/00006676-200011000-00007

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  8 in total

1.  p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb.

Authors:  Berthold Gerdes; Annette Ramaswamy; Andreas Ziegler; Sven A Lang; Michael Kersting; Renate Baumann; Anja Wild; Roland Moll; Matthias Rothmund; Detlef K Bartsch
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

2.  CDKN2A germline mutations in familial pancreatic cancer.

Authors:  Detlef K Bartsch; Mercedes Sina-Frey; Sven Lang; Anja Wild; Berthold Gerdes; Peter Barth; Ralf Kress; Robert Grützmann; Mario Colombo-Benkmann; Andreas Ziegler; Stephan A Hahn; Matthias Rothmund; Harald Rieder
Journal:  Ann Surg       Date:  2002-12       Impact factor: 12.969

Review 3.  Familial pancreatic carcinoma in Jews.

Authors:  Henry T Lynch; Carolyn A Deters; Jane F Lynch; Randall E Brand
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

4.  A Female With Synchronous Multiple Primary Malignant Tumors in the Esophagogastric Junction, Duodenum and Pancreas: Case Report and Review of the Literature.

Authors:  Yongxing Du; Yunjie Duan; Lipeng Zhang; Zongting Gu; Xiaohao Zheng; Zongze Li; Chengfeng Wang
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

Review 5.  Selection criteria for genetic assessment of patients with familial melanoma.

Authors:  Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2009-10       Impact factor: 11.527

6.  A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice.

Authors:  Rebecca Kinkade; Piyali Dasgupta; Adam Carie; Daniele Pernazza; Melanie Carless; Smitha Pillai; Nicholas Lawrence; Said M Sebti; Srikumar Chellappan
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

Review 7.  Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer.

Authors:  Bo Tang; Yang Li; Guangying Qi; Shengguang Yuan; Zhenran Wang; Shuiping Yu; Bo Li; Songqing He
Journal:  Sci Rep       Date:  2015-09-04       Impact factor: 4.379

8.  Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic CDKN2A variants.

Authors:  Kasper A Overbeek; Mar Dm Rodríguez-Girondo; Anja Wagner; Nienke van der Stoep; Peter C van den Akker; Jan C Oosterwijk; Theo A van Os; Lizet E van der Kolk; Hans F A Vasen; Frederik J Hes; Djuna L Cahen; Marco J Bruno; Thomas P Potjer
Journal:  J Med Genet       Date:  2020-06-01       Impact factor: 6.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.